AuricX Overview
- Year Founded
-
2006

- Status
-
Private
- Latest Deal Type
-
Grant
- Financing Rounds
-
1
AuricX General Information
Description
Provider of treatments for Methicillin Resistant Staphylococcus Aureus. The company provides anti-infectives to treat infections arising from strains of Staphylococcus Aureus and other difficult to treat pathogens. It has developed BPH-652, a clinical trial-stage small molecule that has been shown to be effective against multiple strains of Staphylococcus Aureus (S. aureus) in animal models.
Contact Information
Website
www.auricx.comCorporate Office
- 3400 Research Forest Drive
- Suite B4
- The Woodlands, TX 77380
- United States
Corporate Office
- 3400 Research Forest Drive
- Suite B4
- The Woodlands, TX 77380
- United States
AuricX Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
AuricX Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
AuricX FAQs
-
When was AuricX founded?
AuricX was founded in 2006.
-
Where is AuricX headquartered?
AuricX is headquartered in The Woodlands, TX.
-
What industry is AuricX in?
AuricX’s primary industry is Biotechnology.
-
Is AuricX a private or public company?
AuricX is a Private company.
-
What is AuricX’s current revenue?
The current revenue for AuricX is
. -
Who are AuricX’s investors?
Texas Emerging Technology Fund has invested in AuricX.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »